Artículos de revistas
Recommendations For The Management And Treatment Of Systemic Sclerosis [recomendações Sobre Diagnóstico E Tratamento Da Esclerose Sistêmica]
Registro en:
Revista Brasileira De Reumatologia. , v. 53, n. 3, p. 258 - 275, 2013.
10.1590/S0482-50042013000300004
2-s2.0-84884953100
Autor
Sampaio-Barros P.D.
Zimmermann A.F.
Muller C.S.
Borges C.T.L.
Freire E.A.M.
Maretti G.B.
Neto J.F.M.
Salgado M.C.F.
da Cunha Sauma M.F.L.
de Azevedo M.N.L.
Fontenelle S.
Kayser C.
Institución
Resumen
[No abstract available] 53 3 258 275 Johnson, S.R., Feldman, B.M., Hawker, G.A., Classification criteria for systemic sclerosis subsets (2007) J Rheumatol, 34, pp. 1855-1863 Masi, A.T., Rodnan, G.P., Medsger Jr., T.A., Altman, R.D., D'Angelo, W.A., Fries, J.F., Preliminary criteria for the classification of systemic sclerosis (scleroderma) (1980) Arthritis Rheum, 23, pp. 581-590 LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger Jr., T.A., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis (1988) J Rheumatol, 15, pp. 202-205 Walker, J.G., Pope, J., Baron, M., Leclercq, S., Hudson, M., Taillefer, S., The development of systemic sclerosis classification criteria (2007) Clin Rheumatol, 26, pp. 1401-1409 Walker, U.A., Tyndall, A., Czirjak, L., Denton, C., Farge-Bancel, D., Kowal-Bielecka, O., Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base (2007) Ann Rheum Dis, 66, pp. 754-763 LeRoy, E.C., Medsger Jr., T.A., Criteria for the classification of early systemic sclerosis (2001) J Rheumatol, 28, pp. 1573-1576 Poormoghim, H., Lucas, M., Fertig, N., Medsger Jr., T.A., Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients (2000) Arthritis Rheum, 43, pp. 444-451 Avouac, J., Fransen, J., Walker, U.A., Riccieri, V., Smith, V., Muller, C., Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group (2011) Ann Rheum Dis, 70, pp. 476-481 Pavlov-Dolijanovic, S., Damjanov, N.S., Stojanovic, R.M., Vujasinovictupar, N.Z., Stanisavljevic, D.M., Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon (2012) Rheumatol Int, 32, pp. 3039-3045 McGill, N.W., Gow, P.J., Nailfold capillaroscopy: a blinded study of its discriminatory value in scleroderma, systemic lupus erythematosus, and rheumatoid arthritis (1986) Aust N Z J Med, 16, pp. 457-460 Ingegnoli, F., Boracchi, P., Gualtierotti, R., Biganzoli, E.M., Zeni, S., Lubatti, C., Fantini, F., Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nailfold capillaroscopy (2010) Rheumatology (Oxford), 49, pp. 797-805 Cutolo, M., Sulli, A., Pizzorni, C., Accardo, S., Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis (2000) J Rheumatol, 27, pp. 155-160 Wildt, M., Wuttge, D.M., Hesselstrand, R., Scheja, A., Assessment of capillary density in systemic sclerosis with three different capillaroscopic methods (2012) Clin Exp Rheumatol, 30 (2 SUPPL. 71), pp. S50-S54 Muroi, E., Hara, T., Yanaba, K., Ogawa, F., Yoshizaki, A., Takenaka, M., Shimizu, K., Sato, S., A portable dermatoscope for easy, rapid examination of periungueal nailfold capillary changes in patients with systemic sclerosis (2011) Rheumatol Int, 31, pp. 1601-1606 Sebastiani, M., Manfredi, A., Colaci, M., D'Amico, R., Malagoli, V., Giuggioli, D., Ferri, C., Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients (2009) Arthritis Rheum, 61 (5), pp. 688-694 Sebastiani, M., Manfredi, A., Vukatana, G., Moscatelli, S., Riato, L., Bocci, M., Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study (2012) Ann Rheum Dis, 71, pp. 67-70 Bredemeier, M., Xavier, R.M., Capobianco, K.G., Restelli, V.G., Rohde, L.E., Pinotti, A.F., Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis (2004) J Rheumatol, 31, pp. 286-294 Joyal, F., Choquette, D., Roussin, A., Levington, C., Senécal, J.L., Evaluation of the severity of systemic sclerosis by nailfold capillary microscopy in 112 patients (1992) Angiology, 43 (3 PART 1), pp. 203-210 Riboldi, P., Asero, R., Origgi, L., Crespi, S., Meroni, P.L., Sguotti, C., Sabbadini, M.G., Antinuclear antibodies in progressive systemic sclerosis (1985) Clin Exp Rheumatol, 3, pp. 205-211 Kipnis, R.J., Craft, J., Hardin, J.A., The analysis of antinuclear and antinucleolar autoantibodies of scleroderma by radioimmunoprecipitation assays (1990) Arthritis Rheum, 33, pp. 1431-1437 Simeón-Aznar, C.P., Fonollosa-Plá, V., Tolosa-Vilella, C., Espinosa-Garriga, G., Ramos-Casals, M., Campillo-Grau, M., Registry of the Spanish Network for Systemic Sclerosis: Clinical pattern according to cutaneous subsets and immunological status (2012) Semin Arthritis Rheum, 41, pp. 789-800 Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., Registry of the German Network for Systemic Scleroderma: The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement (2008) Rheumatology (Oxford), 47, pp. 1185-1192 Aeschlimann, A., Meyer, O., Bourgeois, P., Haim, T., Belmatoug, N., Palazzo, E., Kahn, M.F., Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: specificity and clinical correlations (1989) Ann Rheum Dis, 48, pp. 992-997 Harvey, G.R., Butts, S., Rands, A.L., Patel, Y., McHugh, N.J., Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis (1999) Clin Exp Immunol, 117, pp. 395-402 Tan, F.K., Arnett, F.C., Reveille, J.D., Ahn, C., Antohi, S., Sasaki, T., Nishi Bona, C.A., Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles (2000) Arthritis Rheum, 43, pp. 2464-2471 Tan, F.K., Arnett, F.C., Antohi, S., Saito, S., Mirarchi, A., Spiera, H., Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases (1999) J Immunol, 163, pp. 1066-1072 Steen, V.D., Autoantibodies in systemic sclerosis (2005) Semin Arthritis Rheum, 35, pp. 35-42 Walker, J.G., Fritzler, M.J., Update on autoantibodies on systemic sclerosis (2007) Curr Opin Rheumatol, 19, pp. 580-591 Kaldas, M., Khanna, P.P., Furst, D.E., Clements, P.J., Wong, W.K., Seibold, J.R., Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials (2009) Rheumatology (Oxford), 48, pp. 1143-1146 Merkel, P.A., Silliman, N.P., Denton, C.P., Furst, D.E., Khanna, D., Emery, P., Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial (2008) Arthritis Rheum, 59, pp. 699-705 van den Hoogen, F.H., Boerbooms, A.M., Swaak, A.J., Rasker, J.J., van Lier, H.J., van de Putte, L.B., Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial (1996) Br J Rheumatol, 35, pp. 364-372 Pope, J.E., Bellamy, N., Seibold, J.R., Baron, M., Ellman, M., Carette, S., A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma (2001) Arthritis Rheum, 44, pp. 1351-1358 Clements, P.J., Furst, D.E., Wong, W.K., Mayes, M., White, B., Wigley, F., High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial (1999) Arthritis Rheum, 42, pp. 1194-1203 Seibold, J.R., Korn, J.H., Simms, R., Clements, P.J., Moreland, L.W., Mayes, M.D., Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial (2000) Ann Intern Med, 132, pp. 871-879 Khanna, D., Clements, P.J., Furst, D.E., Korn, J.H., Ellman, M., Rothfield, N., Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebocontrolled trial (2009) Arthritis Rheum, 60, pp. 1102-1111 Postlethwaite, A.E., Wong, W.K., Clements, P., Chatterjee, S., Fessler, B.J., Kang, A.H., A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease (2008) Arthritis Rheum, 58, pp. 1810-1822 Kawald, A., Burmester, G.R., Huscher, D., Sunderkötter, C., Riemekasten, G., Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study (2008) J Rheumatol, 35, pp. 1830-1837 Tashkin, D.P., Elashoff, R., Clements, P.J., Goldin, J., Roth, M.D., Furst, D.E., Cyclophosphamide versus placebo in scleroderma lung disease (2006) N Engl J Med, 354, pp. 2655-2666 Clements, P.J., Roth, M.D., Elashoff, R., Tashkin, D.P., Goldin, J., Silver, R.M., Scleroderma lung study (SLS): differences in presentation and course of patients with limited versus diffuse systemic sclerosis (2007) Ann Rheum Dis, 66, pp. 1641-1647 Mendoza, F.A., Nagle, S.J., Lee, J.B., Jimenez, S.A., A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset (2012) J Rheumatol, 39, pp. 1241-1247 Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Kazantzi, A., Sirinian, C., Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study (2010) Rheumatology (Oxford), 49, pp. 271-280 Daoussis, D., Liossis, S.N., Tsamandas, A.C., Kalogeropoulou, C., Paliogianni, F., Sirinian, C., Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis (2012) Clin Exp Rheumatol, 30 (2 SUPPL. 71), pp. S17-S22 Spiera, R.F., Gordon, J.K., Mersten, J.N., Magro, C.M., Mehta, M., Wildman, H.F., Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial (2011) Ann Rheum Dis, 70, pp. 1006-1009 Khanna, D., Saggar, R., Mayes, M.D., Abtin, F., Clements, P.J., Maranian, P., A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease (2011) Arthritis Rheum, 63, pp. 3540-3546 Berger, R.G., Featherstone, G.L., Raasch, R.H., McCartney, W.H., Hadler, N.M., Treatment of calcinosis universalis with lowdose warfarin (1987) Am J Med, 83, pp. 72-76 Yoshida, S., Torikai, K., The effects of warfarin on calcinosis in a patient with systemic sclerosis (1993) J Rheumatol, 20, pp. 1233-1235 Cukierman, T., Elinav, E., Korem, M., Chajek-Shaul, T., Low dose warfarin treatment for calcinosis in patients with systemic sclerosis (2004) Ann Rheum Dis, 63, pp. 1341-1343 Lassoued, K., Saiag, P., Anglade, M.C., Roujeau, J.C., Touraine, R.L., Failure of warfarin in treatment of calcinosis universalis (1988) Am J Med, 84, pp. 795-796 Palmieri, G.M., Sebes, J.I., Aelion, J.A., Moinuddin, M., Ray, M.W., Wood, G.C., Treatment of calcinosis with diltiazem (1995) Arthritis Rheum, 38, pp. 1646-1654 Vayssairat, M., Hidouche, D., Abdoucheli-Baudot, N., Gaitz, J.P., Clinical significance of subcutaneous calcinosis in patients with systemic sclerosis. Does diltiazem induce its regression? (1998) Ann Rheum Dis, 57, pp. 252-254 Robertson, L.P., Marshall, R.W., Hickling, P., Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline (2003) Ann Rheum Dis, 62, pp. 267-269 Fuchs, D., Fruchter, L., Fishel, B., Holtzman, M., Yaron, M., Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis (1986) Clin Rheumatol, 5, pp. 527-530 Daoussis, D., Antonopoulos, I., Liossis, S.N., Yiannopoulos, G., Andonopoulos, A.P., Treatment of systemic sclerosisassociated calcinosis: A case report of rituximab-induced regression of CREST-related calcinosis and review of the literature (2012) Semin Arthritis Rheum, 41, pp. 822-829 Saddic, N., Miller, J.J., Miller 3rd, O.F., Clarke, J.T., Surgical debridement of painful fingertip calcinosis cutis in CREST syndrome (2009) Arch Dermatol, 145, pp. 212-213 Bottomley, W.W., Goodfield, M.J., Sheehan-Dare, R.A., Digital calcification in systemic sclerosis: effective treatment with good tissue preservation using the carbon dioxide laser (1996) Br J Dermatol, 135, pp. 302-304 Sparsa, A., Lesaux, N., Kessler, E., Bonnetblanc, J.M., Blaise, S., Lebrun-Ly, V., Treatment of cutaneous calcinosis in CREST syndrome by extracorporeal shock wave lithotripsy (2005) J Am Acad Dermatol, 53 (5 SUPPL. 1), pp. S263-S265 Thompson, A.E., Shea, B., Welch, V., Fenlon, D., Pope, J.E., Calciumchannel blockers for Raynaud's phenomenon in systemic sclerosis (2001) Arthritis Rheum, 44, pp. 1841-1847 Kahan, A., Amor, B., Menkès, C.J., Weber, S., Guérin, F., Degeorges, M., Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial (1987) Angiology, 38, pp. 333-337 Kahan, A., Amor, B., Menkes, C.J., A randomised doubleblind trial of diltiazem in the treatment of Raynaud's phenomenon (1985) Ann Rheum Dis, 44, pp. 30-33 Hummers, L.K., Wigley, F.M., Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma (2003) Rheum Dis Clin North Am, 29, pp. 293-313 Wigley, F.M., Wise, R.A., Seibold, J.R., McCloskey, D.A., Kujala, G., Medsger Jr., T.A., Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis.A multicenter, placebo-controlled, double-blind study (1994) Ann Intern Med, 120, pp. 199-206 Wigley, F.M., Korn, J.H., Csuka, M.E., Medsger Jr., T.A., Rothfield, N.F., Ellman, M., Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study (1998) Arthritis Rheum, 41, pp. 670-677 Scorza, R., Caronni, M., Mascagni, B., Berruti, V., Bazzi, S., Micallef, E., Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study (2001) Clin Exp Rheumatol, 19, pp. 503-508 Rademaker, M., Cooke, E.D., Almond, N.E., Beacham, J.A., Smith, R.E., Mant, T.G., Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study (1989) BMJ, 298, pp. 561-564 Pope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., Prazosin for Raynaud's phenomenon in progressive systemic sclerosis (2000) Cochrane Database Syst Rev, (2). , CD000956 Surwit, R.S., Gilgor, R.S., Allen, L.M., Duvic, M., A doubleblind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma (1984) Arch Dermatol, 120, pp. 329-331 Nguyen, V.A., Eisendle, K., Gruber, I., Hugl, B., Reider, D., Reider, N., Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study (2010) Rheumatology (Oxford), 49, pp. 583-587 Gliddon, A.E., Doré, C.J., Black, C.M., McHugh, N., Moots, R., Denton, C.P., Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril (2007) Arthritis Rheum, 56, pp. 3837-3846 Dziadzio, M., Denton, C.P., Smith, R., Howell, K., Blann, A., Bowers, E., Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteenweek, randomized, parallel-group, controlled trial (1999) Arthritis Rheum, 42, pp. 2646-2655 Shenoy, P.D., Kumar, S., Jha, L.K., Choudhary, S.K., Singh, U., Misra, R., Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a doubleblind randomized cross-over trial (2010) Rheumatology (Oxford), 49, pp. 2420-2428 Schiopu, E., Hsu, V.M., Impens, A.J., Rothman, J.A., McCloskey, D.A., Wilson, J.E., Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis (2009) J Rheumatol, 36, pp. 2264-2268 De La Veja, A.J., Derk, C.T., Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication (2009) Expert Opin Invest Drugs, 18, pp. 23-29 Herrick, A.L., van den Hoogen, F., Gabrielli, A., Tamimi, N., Reid, C., O'Connell, D., Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis (2011) Arthritis Rheum, 63, pp. 775-782 Pope, J., Fenlon, D., Thompson, A., Shea, B., Furst, D., Wells, G., Silman, A., Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis (2000) Cochrane Database Syst Rev, (2). , CD000955 Lukác, J., Rovenskỳ, J., Tauchmannová, H., Zitnan, D., Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial (1985) Drugs Exp Clin Res, 11, pp. 659-663 Abou-Raya, A., Abou-Raya, S., Helmii, M., Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers (2008) J Rheumatol, 35, pp. 1801-1808 Herrick, A.L., Hollis, S., Schofield, D., Rieley, F., Blann, A., Griffin, K., A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis (2000) Clin Exp Rheumatol, 18, pp. 349-356 Wigley, F.M., Seibold, J.R., Wise, R.A., McCloskey, D.A., Dole, W.P., Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis (1992) J Rheumatol, 19 (9), pp. 1407-1414 Langevitz, P., Buskila, D., Lee, P., Urowitz, M.B., Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions (1989) J Rheumatol, 16, pp. 1433-1435 Marasini, B., Massarotti, M., Bottasso, B., Coppola, R., Papa, N.D., Maglione, W., Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon (2004) Scand J Rheumatol, 33, pp. 253-256 Matucci-Cerinic, M., Denton, C.P., Furst, D.E., Mayes, M.D., Hsu, V.M., Carpentier, P., Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial (2011) Ann Rheum Dis, 70, pp. 32-38 Korn, J.H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist (2004) Arthritis Rheum, 50, pp. 3985-3993 Brueckner, C.S., Becker, M.O., Kroencke, T., Huscher, D., Scherer, H.U., Worm, M., Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study (2010) Ann Rheum Dis, 69, pp. 1475-1478 Mercado, U., Arroyo de Anda, R., Avendaño, L., Araiza-Casillas, R., Avendaño-Reyes, M., Metoclopramide response in patients with early diffuse systemic sclerosis.Effects on esophageal motility abnormalities (2005) Clin Exp Rheumatol, 23, pp. 685-688 Johnson, D.A., Drane, W.E., Curran, J., Benjamin, S.B., Chobanian, S.J., Karvelis, K., Metoclopramide response in patients with progressive systemic sclerosis. Effect on esophageal and gastric motility abnormalities (1987) Arch Intern Med, 147, pp. 1597-1601 Nikou, G.C., Toumpanakis, C., Katsiari, C., Charalambopoulos, D., Sfikakis, P.P., Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients (2007) J Clin Rheumatol, 13, pp. 119-123 Verne, G.N., Eaker, E.Y., Hardy, E., Sninsky, C.A., Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction (1995) Dig Dis Sci, 40, pp. 1892-1901 Marie, I., Dominique, S., Levesque, H., Ducrotté, P., Denis, P., Hellot, M.F., Esophageal involvement and pulmonary manifestations in systemic sclerosis (2001) Arthritis Rheum, 45, pp. 346-354 Janiak, P., Thumshirn, M., Menne, D., Fox, M., Halim, S., Fried, M., Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis-a randomized controlled, cross-over trial (2007) Aliment Pharmacol Ther, 26, pp. 1259-1265 Shoenut, J.P., Wieler, J.A., Micflikier, A.B., The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole (1993) Aliment Pharmacol Ther, 7, pp. 509-513 Pakozdi, A., Wilson, H., Black, C.M., Denton, C.P., Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? (2009) Clin Exp Rheumatol, 27 (3 SUPPL. 54), pp. 5-8 Wipff, J., Coriat, R., Masciocchi, M., Caramaschi, P., Derk, C.T., Hachulla, E., Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study (2011) Rheumatology (Oxford), 50, pp. 1440-1444 Kent, M.S., Luketich, J.D., Irshad, K., Awais, O., Alvelo-Rivera, M., Churilla, P., Comparison of surgical approaches to recalcitrant gastroesophageal reflux disease in the patient with scleroderma (2007) Ann Thorac Surg, 84, pp. 1710-1715 Lundberg, A.C., Akesson, A., Akesson, B., Dietary intake and nutritional status in patients with systemic sclerosis (1992) Ann Rheum Dis, 51, pp. 1143-1148 Baron, M., Hudson, M., Steele, R., Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database (2009) J Rheumatol, 36, pp. 2737-2743. , Canadian Scleroderma Research Group Cliff, I.S., Herber, R., Demis, D.J., Control of malabsorption in scleroderma (1966) J Invest Dermatol, 47, pp. 475-483 Alpert, L.I., Warner, R.R., Systemic sclerosis: case presenting with tetracycline-responsive malabsorption syndrome (1968) Am J Med, 45, pp. 468-473 Brown, M., Teubner, A., Shaffer, J., Herrick, A.L., Home parenteral nutrition-an effective and safe long-term therapy for systemic sclerosis-related intestinal failure (2008) Rheumatology (Oxford), 47, pp. 176-179 Parodi, A., Sessarego, M., Greco, A., Bazzica, M., Filaci, G., Setti, M., Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication (2008) Am J Gastroenterol, 103, pp. 1257-1262 Schnabel, A., Reuter, M., Gross, W.L., Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases (1998) Arthritis Rheum, 41, pp. 1215-1220 Yiannopoulos, G., Pastromas, V., Antonopoulos, I., Katsiberis, G., Kalliolias, G., Liossis, S.N., Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease (2007) Rheumatol Int, 27, pp. 357-361 Domiciano, D.S., Bonfá, E., Borges, C.T., Kairalla, R.A., Capelozzi, V.L., Parra, E., A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma (2011) Clin Rheumatol, 30, pp. 223-229 Nannini, C., West, C.P., Erwin, P.J., Matteson, E.L., Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies (2008) Arthritis Res Ther, 10, pp. R124 Tochimoto, A., Kawaguchi, Y., Hara, M., Tateishi, M., Fukasawa, C., Takagi, K., Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up (2011) Mod Rheumatol, 21, pp. 296-301 Seibold, J.R., Denton, C.P., Furst, D.E., Guillevin, L., Rubin, L.J., Wells, A., Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis (2010) Arthritis Rheum, 62, pp. 2101-2108 Nithyanova, S.I., Brough, G.M., Black, C.M., Denton, C.P., Mycophenolate mofetil in diffuse cutaneous systemioc sclerosis-a retrospective analysis (2007) Rheumatology (Oxford), 46, pp. 442-445 Avouac, J., Airò, P., Meune, C., Beretta, L., Dieude, P., Caramaschi, P., Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies (2010) J Rheumatol, 37 (11), pp. 2290-2298. , PMID: 20810505 Galiè, N., Hoeper, M.M., Humbert, M., Torbicki, A., Vachiery, J.L., Barbera, J.A., Guidelines for the diagnosis and treatment of pulmonary hypertension (2009) Eur Heart J, 30 (20), pp. 2493-2537 Badesch, D.B., Tapson, V.F., McGoon, M.D., Brundage, B.H., Rubin, L.J., Wigley, F.M., Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial (2000) Ann Intern Med, 132, pp. 425-434 Caravita, S., Wu, S.C., Secchi, M.B., Dadone, B., Bencini, C., Pierini, S., Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease (2011) Eur J Int Med, 22, pp. 518-521 Channick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F., Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study (2001) Lancet, 358, pp. 1119-1123 Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A., Bosentan therapy for pulmonary arterial hypertension (2002) N Engl J Med, 346, pp. 896-903 Galiè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., Ghofrani, H.A., Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 (2008) Circulation, 117, pp. 3010-3019 Saggar, R., Khanna, D., Shapiro, S., Furst, D.E., Maranian, P., Clements, P., Effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: A prospective single-center, open-label pilot study (2012) Arthritis Rheum, 64, pp. 4072-4077 Galiè, N., Ghofrani, H.A., Torbicki, A., Barst, R.J., Rubin, L.J., Badesch, D., Sildenafil citrate therapy for pulmonary arterial hypertension (2005) N Engl J Med, 353, pp. 2148-2157 Badesch, D.B., Hill, N.S., Burgess, G., Rubin, L.J., Barst, R.J., Galiè, N., Sildenafil for pulmonary arterial hypertension associated with connective tissue disease (2007) J Rheumatol, 34, pp. 2417-2422 Galiè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., Safdar, Z., Tadalafil therapy for pulmonary arterial hypertension (2009) Circulation, 119, pp. 2894-2903 DeMarco, P.J., Weisman, M.H., Seibold, J.R., Furst, D.E., Wong, W.K., Hurwitz, E.L., Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial (2002) Arthritis Rheum, 46, pp. 2983-2989 Walker, J.G., Ahern, M.J., Smith, M.D., Coleman, M., Pile, K., Rischmueller, M., Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment (2003) Intern Med J, 33, pp. 216-220 Penn, H., Howie, A.J., Kingdon, E.J., Bunn, C.C., Stratton, R.J., Black, C.M., Scleroderma renal crisis: patient characteristics and long-term outcomes (2007) QJM, 100, pp. 485-494 Teixeira, L., Mouthon, L., Mahr, A., Berezné, A., Agard, C., Mehrenberger, M., Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients (2008) Ann Rheum Dis, 67, pp. 110-116 Hudson, M., Baron, M., Lo, E., Weinfeld, J., Furst, D.E., Khanna, D., An international, web-based, prospective cohort study to determine whether the use of ACE inhibitors prior to the onset of scleroderma renal crisis is associated with worse outcomes-methodology and preliminary results (2010) Int J Rheumatol, 2010, p. 347402. , doi:10.1155/2010/347402. Epub 2010 Sep 14 Hesselstrand, R., Scheja, A., Wuttge, D., Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor (2012) Scand J Rheumatol, 41, pp. 39-43 Ferri, C., Valentini, G., Cozzi, F., Sebastiani, M., Michelassi, C., La Montagna, G., Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients (2002) Medicine, 81, pp. 139-153 Scussel-Lonzetti, L., Joyal, F., Raynauld, J.P., Roussin, A., Rich, E., Goulet, J.R., Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival (2002) Medicine, 81, pp. 154-167 Ioannidis, J.P., Vlachoyiannopoulos, P.G., Haidich, A.B., Medsger Jr., T.A., Lucas, M., Michet, C.J., Mortality in systemic sclerosis: an international meta-analysis of individual patient data (2005) Am J Med, 118, pp. 2-10 Sampaio-Barros, P.D., Bortoluzzo, A.B., Marangoni, R.G., Rocha, L.F., Del Rio, A.P., Samara, A.M., Survival, causes of death, and prognostic factors in systemic sclerosis: analysis of 947 Brazilian patients (2012) J Rheumatol, 39, pp. 1971-1978 Montisci, R., Vacca, A., Garau, P., Colonna, P., Ruscazio, M., Passiu, G., Detection of early impairment of coronary flow reserve in patients with systemic sclerosis (2003) Ann Rheum Dis, 62, pp. 890-893 Sulli, A., Ghio, M., Bezante, G.P., Deferrari, L., Craviotto, C., Sebastiani, V., Blunted coronary flow reserve in systemic sclerosis (2004) Rheumatology (Oxford), 43 (4), pp. 505-509 Kahan, A., Allanore, Y., Primary myocardial involvement in systemic sclerosis (2006) Rheumatology (Oxford), 45 (SUPPL. 4), pp. iv14-7 Ishida, R., Murata, Y., Sawada, Y., Nishioka, K., Shibuya, H., Thallium-201 myocardial SPET in patients with collagen disease (2000) Nucl Med Commun, 21, pp. 729-734 Akram, M.R., Handler, C.E., Williams, M., Carulli, M.T., Andron, M., Black, C.M., Angiographically proven coronary artery disease in scleroderma (2006) Rheumatology (Oxford), 45, pp. 1395-1398 Kahan, A., Devaux, J.Y., Amor, B., Menkes, C.J., Weber, S., Foult, J.M., Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma (1986) Ann Rheum Dis, 45, pp. 718-725 Kahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Nitenberg, A., Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis (1986) N Engl J Med, 314, pp. 1397-1402 Kahan, A., Devaux, J.Y., Amor, B., Menkes, C.J., Weber, S., Venot, A., Nicardipine improves myocardial perfusion in systemic sclerosis (1988) J Rheumatol, 15, pp. 1395-1400 Kahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Venot, A., The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis (1990) Clin Pharmacol Ther, 47, pp. 483-489 Duboc, D., Kahan, A., Maziere, B., Loc'h, C., Crouzel, C., Menkès, C.J., The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study (1991) Arthritis Rheum, 34, pp. 198-203 Vignaux, O., Allanore, Y., Meune, C., Pascal, O., Duboc, D., Weber, S., Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis (2005) Ann Rheum Dis, 64, pp. 1268-1273 Kahan, A., Devaux, J.Y., Amor, B., Menkès, C.J., Weber, S., Guérin, F., Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis (1990) J Cardiovasc Pharmacol, 15, pp. 249-253 Hegedüs, I., Czirják, L., Left ventricular wall thickness and disease duration in systemic sclerosis (1993) Postgrad Med J, 69, pp. 285-290 Meune, C., Allanore, Y., Pascal, O., Devaux, J.Y., Dessault, O., Duboc, D., Myocardial contractility is early affected in systemic sclerosis: a tissue Doppler echocardiography study (2005) Eur J Echocardiogr, 6, pp. 351-357 Meune, C., Avouac, J., Wahbi, K., Cabanes, L., Wipff, J., Mouthon, L., Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients (2008) Arthritis Rheum, 58, pp. 1803-1809 Meune, C., Allanore, Y., Devaux, J.Y., Dessault, O., Duboc, D., Weber, S., High prevalence of right ventricular systolic dysfunction in early systemic sclerosis (2004) J Rheumatol, 31, pp. 1941-1945 Bernardo, P., Conforti, M.L., Bellando-Randone, S., Pieragnoli, P., Blagojevic, J., Kaloudi, O., Implantable